SCHEMBL4907005

SCHEMBL4907005

N#Cc1c(Cl)nc(NC2CC2)nc1-c1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.41
MAPK14 Q16539 2/20 0.39
ADORA1 P30542 5/20 0.38
ADORA2A P29274 4/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CTSV O60911 1/20 0.37
PLAT P00750 1/20 0.37
CTSL P07711 1/20 0.37
CTSH P09668 1/20 0.37
CTSS P25774 1/20 0.37
CASP14 P31944 1/20 0.37
CTSK P43235 1/20 0.37
CASP6 P55212 1/20 0.37
CTSZ Q9UBR2 1/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MYC P01106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909514 0.88 ADORA1 (0.50) ACHEADORA1ADORA2AKDM4EALDH1A1
SCHEMBL4907027 0.84 ADORA2A (0.47) ADORA1ADORA2AKDM4EALDH1A1HPGD
SCHEMBL4904086 0.80 ACHE (0.43) ACHEALDH1A1CTSSCTSKHPGD
SCHEMBL4906255 0.79 ADORA1 (0.47) ACHEADORA1ADORA2AALDH1A1CTSV
SCHEMBL4899212 0.79 KDM1A (0.47) ACHEADORA1ADORA2AKDM4EALDH1A1
SCHEMBL4907067 0.79 PDE4A (0.44) ACHEKDM4ECTSVPLATCTSL
SCHEMBL4906676 0.79 ACHE (0.43) ACHEADORA1ADORA2ACTSVPLAT
SCHEMBL4909018 0.78 ADORA1 (0.56) ACHEADORA1ADORA2ACTSVPLAT
SCHEMBL4906201 0.77 KMT2A (0.55) ACHEADORA1ADORA2AALDH1A1HPGD
SCHEMBL4899380 0.77 ADORA1 (0.53) ACHEADORA1ADORA2ACTSVPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ACHE 939/4885MAPK14 575/4885ADORA1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.